The expression of matrix metalloproteinase-2 (MMP-2) has been linked with tumor invasion, angiogenesis, and metastasis. However, the molecular basis for MMP-2 overexpression in tumor cells remains unclear. In this study, by using K-1735 melanoma system, we demonstrated that highly metastatic C4, M2, and X21 tumor cells express elevated MMP-2 mRNA and enzymatic activity, whereas poorly metastatic C10, C19, and C23 tumor cells express much lower levels. Moreover, a concomitant elevated Stat3 activity has been detected in these metastatic tumor cells that overexpress MMP-2. Transfection of constitutively activated Stat3 into poorly metastatic C23 tumor cells directly activated the MMP-2 promoter, whereas the expression of a dominant-negative Stat3 in highly metastatic C4 tumor cells inhibited the MMP-2 promoter. A high-affinity Stat3-binding element was identified in the MMP-2 promoter and Stat3 protein bound directly to the MMP-2 promoter. Blockade of activated Stat3 through expression of a dominant-negative Stat3 significantly suppressed MMP-2 expression in the metastatic tumor cells. Therefore, overexpression of MMP-2 in the metastatic melanoma cells can be attributed to elevated Stat3 activity, and Stat3 upregulates the transcription of MMP-2 through direct interaction with the MMP-2 promoter. Furthermore, blockade of activated Stat3 in highly metastatic C4 cells significantly suppressed the invasiveness of the tumor cells, inhibited tumor growth, and prevented metastasis in nude mice. Collectively, these studies suggest that Stat3 signaling directly regulates MMP-2 expression, tumor invasion, and metastasis, and that Stat3 activation might be a crucial event in the development of metastasis.
Introduction
Melanoma is one of the most frequent malignant tumors, and is characterized by its high capacity for invasion and metastasis. Degradation and remodeling of the extracellular matrix (ECM) and basement membranes by proteolytic enzymes are essential steps in these processes. The role of matrix metalloproteinases (MMPs) in tumor invasion and metastasis is well established (Coussens and Werb, 1996; Stetler-Stevenson et al., 1996; Chambers and Matrisian, 1997; Polette and Birembaut, 1998; Curran and Murray, 1999) . In particular, MMP-2, a 72-kDa type IV collagenase, also referred to as gelatinase A, has been shown to be one of the key enzymes in the invasion and metastasis cascade of malignant melanoma (Seftor et al., 1993) . For example, it has been shown that the in vitro invasiveness of melanoma cells through reconstituted basement membranes depends on the activation of MMP-2, whereas MMP-9 was produced in small amounts (Kurschat et al., 1999) . In a xenograft model, increased expression of functionally active MMP-2 correlated with the metastatic capacity of different melanoma cell lines in vivo, indicating that activated MMP-2 may be required for melanoma progression (Hofmann et al., 1999) . In a clinical study, Kurschat et al. (2002) reported the identification of activated MMP-2 as the main gelatinolytic enzyme in malignant melanoma. Furthermore, Hofmann et al. (2000) demonstrated a correlation between the expression and activation of MMP-2 with melanoma progression. An increased MMP-2 expression also correlated with hematogeneous metastasis (Va¨isa¨nen et al., 1996) . Remarkably, it has been shown recently that the expression of MMP-2 protein in malignant melanoma is an independent prognostic factor for patient survival (Va¨isa¨nen et al., 1998) .
MMP-2 also contributes to tumor angiogenesis, which is another essential step of metastasis processes (Liotta et al., 1991; Moses, 1997; Stetler-Stevenson 2001) . The proteolytic activity of MMP-2 may facilitate the migration of endothelial cells through the ECM toward the source of the angiogenic stimulus. In addition, proteolysis of the ECM components by MMP-2 may release stored angiogenic signaling molecules from the ECM. MMP-2 has been shown to be required for the switch to the angiogenic phenotype in a chondrosarcoma model (Fang et al., 2000) . Reduced angiogenesis and metastasis of melanoma have been observed in mice that were genetically modified to lack MMP-2 expression (Itoh et al., 1998) . These studies thereby established the importance of MMP-2 in melanoma metastasis.
The mechanisms accounting for the upregulation of MMP-2 activity in metastatic cells are largely unknown. The activity of MMP-2 is subject to four levels of regulation, including transcriptional regulation, mRNA stability, activation of proenzyme, and inhibition or activation of enzyme through the tissue inhibitors of metalloproteinases (Overall et al., 1991; Harendza et al., 1995; Strongin et al., 1995; Mauviel, 1996; Yu et al., 1996; Bian and Sun 1997; Mertens et al., 1997; Lee et al., 2000) . Increasing evidence suggests that MMP-2 expression is regulated by various cytokines and growth factors, including epidermal growth factor, fibroblast growth factor (Miyake et al., 1997; van der Zee et al., 1998) , and interleukin-6 (Kossakowska et al., 1999) , and by oncogenic proteins such as Src and Ras (Thant et al., 1999; Moon et al., 2000) . Significantly, many tumors often exhibit overexpression of these molecules; and these molecules often transmit signals through the signal transducer and activator of transcription 3 (Stat3) (Zhong et al., 1994; Yu et al., 1995) . Therefore, it is highly probable that Stat3 activation is a common signaling intermediate leading to the overexpression of MMP-2 in malignant tumors. This notion is apparently supported by the fact that constitutively activated Stat3 protein has been found in various types of tumors, including leukemia; cancers of the breast, head and neck, pancreas, and prostate; and melanoma (Watson and Miller 1995; Gouilleux-Gruart et al., 1996; Grandis et al., 2000; Ni et al., 2000; Niu et al., 2002a, b; Wei et al., 2003) .
Stat3, a member of the JAK-STAT signaling pathway , is a latent transcription factor. Upon activation, Stat3 is phosphorylated on tyrosine residue by activated Jak kinases in receptor complexes, leading to the formation of homo-and heterodimers and translocation to the nucleus, where they regulate transcription. Recent studies have revealed that altered Stat3 could contribute to the oncogenesis (Bromberg et al., 1999) . Activation of Stat3 has been observed in cells transformed in vitro with v-src and v-abl oncogenes (Danial et al., 1995; Yu et al., 1995) . Overexpression of the constitutively activated Stat3 mutant (Stat3-C) into immortalized NIH 3T3 fibroblasts induced cellular transformation and tumor formation in nude mice (Bromberg et al., 1999) . In addition, inhibition of activated Stat3 by a dominant-negative Stat3 variant suppresses the growth of murine melanoma B16 tumors in vivo (Niu et al., 1999) . However, it is unknown whether Stat3 activation critically regulates the metastatic behavior of melanoma.
In the present study, we set out to determine whether and, if so, how the Stat3 signaling pathway regulates MMP-2 expression, the invasiveness and metastasis of melanoma cells. We have found that Stat3 activity correlates with MMP-2 expression, tumor invasiveness, and metastasis in the melanoma cells. Furthermore, we found that Stat3 directly binds to the promoter of MMP-2 gene and upregulates its expression. Blockade of activated Stat3 by ectopic expression of dominantnegative Stat3 significantly suppressed MMP-2 expression in and the invasiveness of tumor cells, inhibited tumor growth, and prevented metastasis in nude mice. Our results demonstrate that activation of the Stat3 signaling pathway directly contributes to the overexpression of MMP-2 in highly metastatic melanoma cells, and is critical for tumor invasiveness and metastasis.
Results
Increased MMP-2 expression in highly invasive and metastatic melanoma cells
In the first set of experiments, we examined the metastatic potential of the K1735 nonmatastatic or poorly metastatic clones (C10, C19, and C23), and highly metastatic clones (C4, M2, and X21) in nude mice. As shown in Table 1 , C10, C19, and C23 cells produced no or few lung metastases. In contrast, cells from clones C4, M2, and X21 produced many lung metastases. These results are consistent with previous reports that used syngeneic C3H/HeN mice (Talmadge and Fidler, 1982; Aukerman et al., 1986; Fidler and Talmadge, 1986 ). We then determined the level of MMP-2 expression in highly metastatic clones (C4, M2, and X21) and nonmetastatic or poorly metastatic clones (C10, C19, and C23) of the murine K-1735 melanoma. Tumor cells from all six cell lines (80% confluent) were incubated in serum-free medium for 24 h. The levels of MMP-2 and MMP-9 enzymatic activity in the supernatants were determined using a gelatin zymography assay. All the cells expressed similar, but very low levels In total, 5 Â 10 4 cells were injected i.v. into groups of nude mice (n ¼ 5). The mice were killed on day 28 or when they became moribund. The number of experimental lung metastases was determined with the aid of a dissecting microscope. Results expressed as median number and range of lung metastatic nodules. * Po0.001 as compared with poorly metastatic cells
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T-x Xie et al of MMP-9 enzymatic activity ( Figure 1a) . However, metastatic C4, M2, and X21 cells exhibited a higher level of MMP-2 activity than did poorly metastatic or nonmetastatic C10, C19, and C23 cells (Figure 1a) . The MMP-2 activity was consistent with MMP-2 mRNA expression as determined using Northern blot analysis (Figure 1b) . Also, the level of MMP-2 expression directly correlated with the tumor cells' invasive potential (Figure 1c) . Moreover, anti-MMP-2 monoclonal antibody (10 mg/ml) reduced the invasiveness of C4 cells by 53 þ 6.2% (data not shown). Therefore, the metastatic melanoma cells express higher levels of MMP-2, which plays an important role in tumor invasion.
Increased Stat3 DNA-binding activity and phosphorylation in highly metastatic melanoma cells
To determine the level of Stat3 activation in tumor cells, nuclear protein extracts were prepared from C10, C19, C23, C4, M2, and X21 cells. We first examined whether Stat3 is activated in tumor cells using electrophoretic mobility shift assay (EMSA) with a radiolabeled, double-stranded oligonucleotide probe containing a consensus-binding motif for Stat3 (Figure 2a) . We found that Stat3 DNA-binding activity was detected in Figure 1 MMP-2 expression and functional analysis. (a) Gelatinase assay. K-1735 C10, C19, C23, C4, M2, and X21 tumor cells (80% confluent) were incubated in serum-free medium for 24 h. MMP-2 and MMP-9 enzymatic activity in supernatants was determined using a zymography assay. (b) Northern blot analysis. Cellular mRNA was prepared from tumor cells, and MMP-2 mRNA expression was determined using Northern blot analysis. Equal mRNA sample loading was monitored by hybridizing the same membrane filter with a glyceraldehyde-3-phosphate dehydrogenase cDNA probe. (c) Invasion assay. Tumor cells were seeded into the upper compartments of six-well invasion chambers and incubated for 6 h. The tumor cells that migrated through the Matrigel were counted under a microscope. The number of migrated cells that penetrated through the Matrigel-coated filters was expressed as the average number of cells in 10 randomly selected fields identified within the lower surface of the filter. The standard deviation bars represent triplicates within the assay. Results shown here are for one representative experiment of two Figure 2 Stat3 DNA-binding activity and phosphorylation in tumor cells. (a) Stat3 DNA-binding activity. Nuclear protein extracts (10 mg/sample) were subjected to EMSA using 32 P-labeled oligonucleotide probes containing a consensus-binding motif for Stat3. In some reactions, unlabeled Stat3 consensus probe (X21 þ cold wt) or its mutant (X21 þ cold mut) or anti-Stat3 antibodies (X21 þ Ab) were added. The positions of the Stat3 and supershifted complexes are marked. (b) Western blot analysis. K-1735 C10, C19, C23, C4, M2, and X21 cells were cultured at 80% confluence. Whole-cell extracts were prepared, and the expression of activated Stat3 protein was determined using Western blot analysis with a specific antiphosphotyrosine-Stat3 antibody. The expression of total Stat3 protein was determined by hybridizing the same membrane filter with an antiStat3 antibody. As a positive control (c), whole-cell protein was prepared from C19 cells treated with 10 U/ml interferon-a for 1 h. Equal protein sample loading was monitored by hybridizing the same membrane filter with an anti-b-actin antibody
T-x Xie et al K-1735 tumor cells and that highly metastatic tumor cells had much higher levels of Stat3 DNA-binding activity than poorly metastatic cells did. The Stat3 DNA-binding activity was specifically competed with unlabeled Stat3 consensus probe, but not with Stat3 mutant probe ( Figure 2a) . Moreover, the DNA-protein complex was supershifted by Stat3-specific antibodies (Figure 2a ), but not by Stat1 antibodies (data not shown). These results demonstrated that Stat3 was constitutively activated at higher levels with respect to highly metastatic tumor cell lines and that increased Stat3 activity directly correlated with increased levels of MMP-2 expression. Increased Stat3 activation can occur through several potential mechanisms, including increased Stat3 phosphorylation. To determine whether the observed increased Stat3 activation was associated with increased protein phosphorylation, the levels of tyrosine-phosphorylated Stat3 were examined by Western blot analysis using antiphosphotyrosine-Stat3 (Tyr705) antibody in whole-cell lysates of the above cell lines. Tyrosine-phosphorylated Stat3 (PY-Stat3) was clearly detected at high levels in highly metastatic C4, M2, and X21 cells, whereas C10, C19, and C23 cells expressed only negligible phosphorylated Stat3 (Figure 2b ). All the cells expressed similar levels of total Stat3 protein ( Figure 1b ). These data demonstrated that the increased Stat3 activity in highly metastatic cells was due at least in part to increased Stat3 phosphorylation.
Transactivation of MMP-2 promoter by Stat3-c and repression of MMP-2 promoter by Stat3-DN
To assess the effect of Stat3 on MMP-2 transcription, the MMP-2 promoter-luciferase construct pMLuc was cotransfected into C23 cells with an increased concentration of a constitutively activated Stat3 expression vector (Stat3-C) or control vector pcDNA 3.1. Stat3-C was generated by point mutation of cysteine residues at A662 and N664 of the Stat3 molecule. This mutant Stat3-C is a constitutively activated molecule that dimerizes spontaneously and is capable of binding DNA and activating transcription (Bromberg et al., 1999) . Luciferase activity driven by the MMP-2 promoter was activated by Stat3-C in C23 cells in a dose-dependent manner ( Figure 3a) .
Conversely, pMLuc was cotransfected into C4 cells with an increased concentration of a dominant-negative Stat3 (Stat3-DN) expression vector. This dominantnegative Stat3 construct contains a phenylalanine substitution of the tyrosine residue position at 705, which results in a reduction of tyrosine phosphorylation of wild-type Stat3 and inhibition of endogenous Stat3 activation (Kaptein et al., 1996; Nakajima et al., 1996) . Luciferase activity driven by the MMP-2 promoter was inhibited by Stat3-DN in C4 cells (Figure 3b ).
Direct interaction of Stat3 with the MMP-2 promoter
We first analysed the sequences of the MMP-2 promoter for potential Stat-binding elements with the consensus sequences TT (N4) AA and TT (N5) AA (Seidel et al., 1995) . Seven putative Stat-binding elements (referred to as DNA sequences #1-7) were identified in the MMP-2 promoter region ( Figure 4a ). We then synthesized oligonucleotides corresponding to these seven potential Stat3-binding elements. Using EMSA competition experiments, we tested whether each potential Stat3-binding element competed with the Stat3 consensusbinding motif (Santa Cruz Biotechnology) for the binding of Stat3. As shown in Figure 4b , binding of Stat3 consensus-binding motif to Stat3 protein was abrogated by an excess of unlabeled double-stranded DNA sequence #6 (from À625 to À601 upstream of the transcription initiation site). Unlabeled double-stranded To provide direct evidence that Stat3 binds to the MMP-2 promoter, the double-stranded oligonucleotides of the putative Stat3-binding element #6 and #7 were radiolabeled and used as probes for EMSA; Stat3 consensus-binding motif was used as a control. EMSA was performed using nuclear protein prepared from C4 cells (Figure 4c ). Incubation of protein extracts with the #6 probe resulted in the formation of one major shifted band (DNA-protein complex) (lane 3), which was as strong as the band observed in the incubation of protein extracts with the consensus Stat3 probe (lane 2) (Figure 4c) . Moreover, the shifted band could be competed out by unlabeled consensus Stat3 probe (lane 4) and supershifted by Stat3 antibody (lane 5), indicating that the shifted band represented a Stat3 DNA-protein complex. #7 probe was also able to bind to Stat3 protein (lane 6), but with less affinity than the consensus Stat3 motif; and the shifted band could be competed out by unlabeled consensus Stat3 probe (lane 7) and supershifted by Stat3 antibody (lane 8) (Figure 4c ). These experiments indicated that Stat3 binding elements are present within the MMP-2 promoter and that TTTCCCAA at positions À617 to À610 is a high-affinity Stat3-binding element.
To provide direct evidence that the Stat3 binding site within the 625-bp proximal MMP-2 promoter actually contributed to Stat3-induced MMP-2 transcription, we performed site-directed mutagenesis of the Stat3 binding site in pGL2 luciferase driven by 625-bp MMP-2 promoter. A base-pair change from TT (at positions -616 and -617) to CG in this Stat3-binding element significantly eliminated MMP-2 promoter transactivation by Stat3-C in C23 cells (Figure 4d ). These results suggested that the Stat3-binding site within the 625-bp proximal MMP-2 promoter was required for MMP-2 promoter activation by Stat3. Collectively, these results provide evidence that Stat3 transactivates MMP-2 through direct binding to the MMP-2 promoter.
Enforced downregulation of constitutive Stat3 activity and inhibition of MMP-2 expression in and the invasiveness of tumor cells
To further determine the effect of altered Stat3 activity on MMP-2 expression, C4 cells were transfected with Stat3-DN expression vector. Stable transfectants containing the Stat3-DN or control vector were selected in the presence of G418. Nuclear protein extracts were prepared from parental C4, vector control, and Stat3-DN-transfected cells, and Stat3-binding activity was determined by EMSA. Densitometric measurements indicated that the levels of Stat3 activation in three of the representative transfectants containing Stat3-DN (C4-DN-a, -b, and -c) were decreased 63, 79, or 71% as compared to parental C4 cells (Figure 5a ). Moreover, enforced expression of Stat3-DN in C4 cells significantly suppressed MMP-2 promoter activity as determined using the dual luciferase assay system (Figure 5b ), significantly suppressed MMP-2 mRNA as determined using Northern blot analysis (Figure 6a) , and significantly suppressed MMP-2 enzyme activity as determined using zymography (Figure 6b ). These results indicated that blockade of constitutive Stat3 activity suppressed MMP-2 expression. DN-a, -b , and -c). MMP-2 mRNA expression was determined using Northern blot analysis. Equal mRNA sample loading was monitored by hybridizing the same membrane filter with a glyceraldehyde-3-phosphate dehydrogenase cDNA probe. (b) Gelatinase activity assay. Tumor cell lines listed above (80% confluent) were incubated in serum-free medium for 24 h. The level of MMP-2 enzymatic activity in the supernatants was determined using zymography. (c) Invasion assay. Tumor cell lines were seeded into the upper compartments of six-well invasion chambers and incubated for 6 h. The tumor cells that migrated through the Matrigel were counted under a microscope. The number of migrated cells that penetrated through the Matrigel-coated filters was expressed as the average number of cells in 10 randomly selected fields identified within the lower surface of the filter
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T-x Xie et al palpable tumors within 8 days and reached 1.0-1.3 cm in mean diameter within 20 days (Figure 7) . In contrast, the tumors resulting from injection of Stat3-DNtransfected cells were much smaller with longer latency (Figure 7) .
To evaluate experimental metastases, 0.2 ml of tumorcell suspension (5 Â 10 4 cells/mouse) was injected into the lateral tail veins of nude mice. The mice were killed 28 days after tumor-cell injection or when they had become moribund. As shown in Table 2 , C4 and C4-Neo cells produced a large number of metastatic nodules in all injected mice. In contrast, the Stat3-transfected C4-DN cells did not produce metastatic nodules in any mice injected with these tumor cells ( Table 2) .
To determine whether the inhibition of tumor growth and the suppressed capacity to produce metastases by C4-DN cells in vivo was due to different growth rates in vitro, we compared their doubling time with that of control cells in cultures. The mean doubling time for parental and neo-transfected cells was 16.4 and 15.6 h, respectively, while the mean doubling time for Stat3-DN-transfected cells (C4-DN-a, -b, and -c) was 16.2, 17.0, and 16.5 h, respectively. Therefore, we found that the cell doubling time for C4 and C4-Neo cells was indistinguishable from that for the C4-DN cells. These results suggested that Stat3 blockade directly suppresses tumor growth and metastasis.
Discussion
In the present study, we have demonstrated that Stat3 plays an important role in regulating MMP-2 expression, tumor invasion, and metastasis of melanoma cells. MMP-2 has been described as a key proteolytic enzyme in melanoma invasion (Seftor et al., 1993) and as an independent prognostic factor for patient survival (Va¨isa¨nen et al., 1998) . Consistent with these results, we detected a predominantly elevated MMP-2 expression in highly invasive and metastatic K1735 melanoma cells. Only very low levels of MMP-9 were detected. In addition, we have found that inhibition of MMP-2 activity in the highly metastatic cells suppressed the invasiveness of these cells, indicating the importance of MMP-2 in melanoma invasion. The mechanism by which metastatic melanoma cells increase MMP-2 expression was unclear. Here, we provide evidence for the first time that in metastatic melanoma cells, increased MMP-2 expression can be attributed to increased constitutive Stat3 activity, and that Stat3 serves as a positive regulator of MMP-2 expression in the melanoma cells. Indeed, blockade of activated Stat3 in highly metastatic K1735 melanoma cells significantly suppressed MMP-2 expression, tumor invasion, and metastasis. Thus, our results suggested an involvement of Stat3 activation in the molecular control of invasion and metastasis of melanoma.
Several groups have studied the transcriptional regulation of MMP-2 by other transcription factors, such as p53 (Harendza et al., 1995; Bian and Sun 1997; Mertens et al., 2002 , Yan et al., 2002 . A highly conserved enhancer element mapped between bp À1657 and À1619 in the human 5 0 -flanking region (denoted r2), and between bp À1048 and 1008 in the rat (denoted RE-1) (Bian and Sun 1997; Mertens et al., 1997) . This enhancer element might be responsible for the induction of MMP-2 by genotoxic stresses such as irradiation . A Stat3-binding site had been identified in RE-1 . However, since this putative Stat3-binding site overlaps with binding sites for p53 and YB-1, mapping of Stat3 comes in contact with the DNA by mutagenesis of this sequence, which will most likely also affect the binding of other proteins. Therefore, the function of Stat3 in the transcription regulation of MMP-2 was unclear. In the present study, we identified a high-affinity Stat3-binding element mapped between bp À617 and À610 of the proximal MMP-2 promoter. The Stat3-binding affinity of this element was higher than the Stat3-binding site 
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T-x Xie et al mapped between bp À1657 and À1619. Mutation of this Stat3-binding element significantly eliminated MMP-2 promoter transactivation by constitutive activated Stat3, indicating this Stat3-binding element within the 625-bp proximal MMP-2 promoter was required for MMP-2 promoter activation by Stat3. Moreover, to provide causal evidence of the relationship between constitutive Stat3 activation and MMP-2 overexpression, we used the well-established dominant-negative Stat3 expression system. We were able to show that blockade of constitutive Stat3 activity significantly downregulated the expression of MMP-2 in metastatic melanoma cells. Thus, our results demonstrated that Stat3 regulates MMP-2 expression through direct interaction with the MMP-2 promoter via a Stat3-binding element or elements on the MMP-2 promoter. Stat3 is constitutively activated in the majority of melanoma cell lines and human melanoma specimens (Niu et al., 2002a) . Our data provided the first evidence for the essential role of activated Stat3 in metastasis of melanoma. This conclusion is based on the results showing that enforced expression adominant-negative Stat3, which significantly suppressed Stat3 activation, prevented metastasis of melanoma cells in vivo. Our data indicate that Stat3 regulates the expression of an invasion-related gene MMP-2, which may suggest a novel mechanism for the contribution of Stat3 activation to metastasis. Furthermore, the inhibition of metastasis by inhibition of Stat3 activation could have resulted from multiple events. For example, we and others have demonstrated that activated Stat3 directly upregulates vascular endothelial growth factor (VEGF) transcription (Niu et al., 2002b; Wei et al., 2003) . Thus, activated Stat3 may contribute to tumor angiogenesis by regulating VEGF as well as MMP-2, which is also implicated in the process of angiogenesis. In addition, cell cycle regulators such as cyclin D1 have been found to be transcriptionally upregulated by Stat3 (Bromberg et al., 1999) . Expression of the oncogene c-myc, which is involved in cell transformation and apoptosis, is increased by Stat3 activation (Nakajima et al., 1996) . Activated Stat3 also downregulates death receptor Fas transcription through its cooperation with c-Jun (Ivanov et al., 2001) . Abrogation of activated Stat3 has been shown to decrease the expression of antiapoptotic genes Bcl-xL and Mcl-1 Niu et al., 2002a) . Therefore, Stat3 may enhance tumor growth and metastasis inclusively by affecting the expression of genes related to cell survival, cell cycle, invasion, and angiogenesis.
In summary, in the present study, we showed that constitutively activated Stat3 is increased in highly invasive and metastatic melanoma cells and directly contributes to the overexpression of MMP-2. Blockade of activated Stat3 inhibited MMP-2 expression in and the invasion and metastasis of melanoma cells. These studies suggest that activation of the Stat3 signaling pathway is critical for tumor invasion and metastasis and that targeting of Stat3 signaling may be a novel approach to controlling tumor invasion and metastasis.
Materials and methods

Animals
Specific pathogen-free female athymic BALB/c nude mice were purchased from the Animal Production Area of the National Cancer Institute, Frederick Cancer Research Facility (Frederick, MD, USA). The mice were housed in laminar flow cabinets under specific pathogen-free conditions and used when they were 6-8 weeks old. The animals were maintained in facilities approved by the Association for Assessment and Accreditation of Laboratory Animal Care in accordance with the current regulations and standards of the US Department of Agriculture, Department of Health and Human Services, and National Institutes of Health.
Cell lines and culture conditions
An original K-1735 melanoma was induced in a C3H/HeN mouse by exposure to UV light followed by painting with croton oil (Kripke, 1979) . The parental tumor was cloned in vitro using a double-dilution method (Fidler and Talmadge 1986) . Of the large number of clones thus isolated, clones 10, 19, and 23 (designated C10, C19, and C23) were classified as nonmetastatic or poorly metastatic (Aukerman et al., 1986) . Clones 4, M2, and X21 (C4, M2, and X21), in contrast, were highly metastatic in the syngeneic mice (Fidler and Talmadge, 1986; Talmadge and Fidler, 1982) . All of the K-1735 cell lines were passaged six to 10 times from the original cloning procedure or isolated from metastases. The cultures were maintained for no longer than 3 weeks after recovery from frozen stocks. All cell lines were maintained as adherent monolayers in Eagle's minimal essential medium supplemented with 10% fetal bovine serum, sodium pyruvate, nonessential amino acids, L-glutamine, and a two-fold vitamin solution (CMEM; Flow Laboratories, Rockville, MD, USA). Cultures were maintained on plastic and incubated in 5% CO 2 -95% air at 371C. All of the cultures were free of mycoplasma infection and the following murine viruses: retrovirus type 3, pneumonia virus, K virus, Theiler's murine encephalomyelitis virus, Sendai virus, minute virus, mouse adenovirus, mouse hepatitis virus, lymphocytic choriomeningitis virus, ectromelia virus, and lactate dehydrogenase virus (assayed by M.A. Bioproducts, Walkersville, MD, USA).
Cell doubling time
Tumor cells were seeded in 24-well plates (3 Â 10 4 /well) at day 0, and hemocytometric count was performed daily. All measurements were performed in triplicate. The cell doubling time was determined from the logarithmic growth phase.
Gelatin zymography
Zymography was performed using a minor modification of the procedure described (Huang et al., 2001) . Tumor cells (2 Â 10 5 ) were seeded in six-well plates and incubated overnight at 371C. The cells were washed twice with Hanks' balanced salt solution and cultured for an additional 24 h in serum-free medium. Culture supernatants were collected for assays of collagenase activity; cells attached to the plate were stained for viability with trypan blue, and the viable cells were counted. Culture supernatants (40 ml) were resolved on a 7.5% sodium dodecyl sulfate polyacrylamide gel that contained 1 mg/ml gelatin (Sigma Chemical Co., St Louis, MO, USA). The gel was washed for 30 min at room temperature in buffer (50.0 mM Tris-HCl, pH 7.5, 15.0 mM CaCl 2 , 1.0 mM ZnCl 2 , and 2.5% Triton X-100) and then incubated for 24 h at 371C in the same buffer but with Triton X-100 at a final concentration of 1%. The gel was then stained with 0.1% Coomassie Brilliant Blue R-250. Clear zones against the blue background indicated the presence of gelatinolytic (i.e. collagenase) activity.
Matrigel invasion assay
An in vitro invasion assay was performed following a previously described procedure with minor modifications (Huang et al., 2001) . Polyinylprolidone-free polycarbonate filters (8-mm pores; Nucleopore; Becton Dickinson Labware, Franklin Lakes, NJ, USA) were coated with a mixture of basement membrane components (Matrigel, 50 mg/filter) and placed in modified Boyden chambers. NIH 3T3 fibroblastconditioned medium in the lower compartment served as a chemoattractant. The tumor cells (2 Â 10 5 ) were seeded in the upper compartment of the Boyden chamber with minimal essential medium containing 0.1% bovine serum albumin and incubated for 6 h at 371C. Then the cells on the upper surface of the filter were completely removed by use of cotton swabs. The cells on the lower surface of the filter were stained with Diff-Quick (American Scientific Products, McGraw Park, IL, USA). Cells were counted at Â 400 in 10 randomly selected fields, and the mean number of cells per field was recorded. To examine the role of MMP-2 in the invasiveness of melanoma cells, the monoclonal antibody that neutralizes the activity of MMP-2 (10 mg/ml) (CA-4001, Oncogene Science, San Diego, CA, USA) was added to C4 cell suspensions before the assay.
Tumor growth and metastasis
To prepare tumor cells for inoculation, cells in the exponential growth phase were harvested by brief exposure to a solution of 0.25%. trypsin and 0.02% EDTA (wt/vol). Cell viability was determined using trypan blue exclusion, and only single-cell suspensions that were greater than 95% viable were used. To study the kinetics of tumor formation, tumor cells were injected s.c. into BALB/c nude mice (1 Â 10 5 cells/mouse) in groups of five. The diameter of each resulting tumor was measured twice a week; a tumor with a diameter greater than 2 mm was recorded as indicative of positive tumor formation. Also, the latency of tumor formation was determined according to the number of days from the tumor-cell injection to observation of a tumor diameter greater than 2 mm (Huang et al., 1998) . To evaluate experimental lung metastasis, 0.2 ml of the tumor-cell suspensions (5 Â 10 4 cells/mouse) were injected into the lateral tail veins of unanesthetized mice. The mice were killed 28 days after the tumor-cell injection or when they had become moribund. Their lungs were then removed and fixed in Bouin's solution for 24 h to permit differentiation of the neoplastic lesions from the organ parenchyma. The lung metastases were counted in a double-blind manner with the aid of a dissecting microscope as described previously (Huang et al., 1998) .
Northern blot analysis
For Northern blot analysis, tumor cells were cultured in vitro at 75-80% confluence. Cellular mRNA was then extracted using a FastTrack mRNA isolation kit (Invitrogen, San Diego, CA, USA). The mRNA (2 mg) was separated electrophoretically onto a 1% denaturing formaldehyde agarose gel, transferred to a GeneScreen nylon membrane (DuPont, Boston, MA, USA) in 20 Â standard saline citrate, and UVcrosslinked using a UV-Stratalinker 1800 (Stratagene, La Jolla, CA, USA). In addition, the MMP-2 cDNA probe was labeled with [
32 P]deoxycytidine triphosphate using a random labeling kit (Boehringer Mannheim Biochemicals, Indianapolis, IN, USA). Equal loading of mRNA samples was monitored by hybridizing the same membrane filter with a rat glyceraldehyde-3-phosphate dehydrogenase cDNA probe (Huang et al., 2001 (Huang et al., , 2002 .
Western blot analysis
Whole-cell lysates were prepared from cancer cell lines. Standard Western blotting was performed using a polyclonal rabbit antibody against activated mouse Stat3 (Phospho-Stat3 [tyr-705] ; New England BioLabs, Beverly, MA, USA), or a anti-Stat3 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and a second antibody (anti-rabbit IgG, a horseradish peroxidase-linked F(ab')2 fragment obtained from a donkey; Amersham Life Sciences, Arlington Heights, IL, USA). Equal protein sample loading was monitored by hybridizing the same membrane filter with an anti-b-actin antibody (Huang et al., 2001 (Huang et al., , 2002 . The probe proteins were detected using the Amersham-enhanced chemiluminescence system according to the manufacturer's instructions.
Promoter reporters and site-specific mutagenesis pGL2-Basic firefly luciferase reporter (Promega) driven by the full-length MMP-2 promoter (pMLuc) (Bian and Sun 1997; Luca et al., 1997) was used in our study. pGL2-Basic firefly luciferase reporter driven by 625-bp MMP-2 promoter (pM625) was generated by polymerase chain reaction and verified by sequencing the inserts and flanking regions of the plasmid. The pM625 mutant at positions À616 and À617 (TT mutated to CG) was generated by using the QuickChange SiteDirected Mutagenesis kit (Stratagene) and confirmed by sequencing.
Dual luciferase assays
Melanoma cells (1 Â 10 5 ) growing in six-well plates were transfected with the indicated reporter plasmids using the Lipofectin reagent (Life Technologies, Inc., Gaithersburg, MD, USA). Transfection efficiency was normalized by cotransfection with a pB-actin-RL reporter containing a fulllength renilla luciferase gene under the control of a human b-actin promoter (Huang et al., 1998) . In some experiments, the reporters were cotransfected with Stat3-C or Stat3-DN (Nakajima et al., 1996; Bromberg et al., 1999) . At 6 h after transfection, the medium was replaced with serum-containing medium, and the cells were then incubated for an additional 48 h at 371C. Both the firefly luciferase and renilla luciferase activities were quantified using the dual luciferase assay system (Promega Corp., Madison, WI, USA). Specific MMP-2 promoter activity was calculated as described (Huang et al., 1998) .
EMSA and supershift assay
Nuclear protein extracts were prepared as described before (Huang et al., 1998; Wei et al., 2003) . Protein concentrations were determined using the Coomassie Plus Protein Assay kit (Pierce Biotechnology, Rockford, IL, USA), according to the manufacturer's protocol. Nuclear protein extracts (10 mg each) were incubated in a final volume of 20 ml of 10 mM HEPES, pH 7.9, 80 mM NaCl, 10% glycerol, 1 mM dithiothreitol, 1 mM EDTA, and 100 mg/ml poly(deoxyinosinic-deoxycytidylic acid) using EMSA with the radiolabeled double-stranded Stat3 consensus-binding motif 5 0 -GATCCTTCTGGGAATTCCTA-GATC-3 0 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or as indicated for 20 min at room temperature. For supershift analyses, the cell extracts were preincubated with specific antibodies against Stat3 (Zymed Laboratories, Inc., San Francisco, CA, USA). Protein-DNA complexes were resolved on a 4.5% nondenaturing polyacrylamide gel containing 2.5% glycerol in 0.25 Â Tris-borate EDTA at room temperature. The gels were then autoradiographed. EMSA images were scanned using a densitometer. The extent of Stat3 activation in each cell line was calculated as the intensity ratio of the Stat3 band in each cell line per the intensity of the Stat3 band in C4 cells.
Stable Stat3-DN transfection
C4 cells were transfected with the dominant-negative Stat3 (Stat3-DN) plasmid using LipofectAMINE (Life Technologies, Inc., Rockville, MD, USA). C4 cells were also transfected with the pcDNA3.1 control vector. Cells were then selected with a standard medium containing 500 mg/ml G418 (GIBCO BRL) for 14 days. Three independent transfections of Stat3-DN expression vector were carried out in K-1735 C4 cells, and G418-resistant colonies were pooled to establish stable C4 Stat3-DN transfectants (C4-DN-a, -b, and -c).
Statistical analysis
The significance of the in vitro data was determined using Student's t-test (two-tailed), while the significance of the differences between the median values of the in vivo data was determined using the two-tailed Mann-Whitney test. P-values less than 0.05 were deemed statistically significant. Abbreviations MMP, matrix metalloproteinase; Stat3-C, constitutively activated mutant of Stat3; Stat3-DN, dominant-negative mutant of Stat3; EMSA, electrophoretic mobility shift assay.
